Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.
until further notice
SourceJournal of Antimicrobial Chemotherapy, 65, 10, (2010), pp. 2188-2194
1 oktober 2010
Article / Letter to editor
Display more detailsDisplay less details
Journal of Antimicrobial Chemotherapy
SubjectN4i 2: Invasive mycoses and compromised host; N4i 3: Poverty-related infectious diseases; NCEBP 13: Infectious diseases and international health; NCMLS 5: Membrane transport and intracellular motility; NCEBP 13: Infectious diseases and international health
OBJECTIVES: To manage the interaction between fosamprenavir/ritonavir and posaconazole, we hypothesized that ritonavir can be replaced by posaconazole as an alternative booster of fosamprenavir with no significant influence on posaconazole pharmacokinetics. METHODS: This was an open-label, randomized, three period, cross-over, single-centre trial in 24 healthy volunteers. All subjects received the following three treatments for 10 days, separated by washout periods of 17 days: posaconazole 400 mg twice daily; fosamprenavir/ritonavir 700/100 mg twice daily; posaconazole 400 mg twice daily with fosamprenavir 700 mg twice daily. RESULTS: Twenty subjects completed the trial. Geometric mean ratios (GMR; +90% confidence interval) of posaconazole AUC and C(max) when taken with fosamprenavir versus posaconazole alone were 0.77 (0.68-0.87) and 0.79 (0.71-0.89), respectively. The GMRs of amprenavir AUC and C(max) when taken as fosamprenavir and posaconazole versus fosamprenavir/ritonavir were 0.35 (0.32-0.39) and 0.64 (0.55-0.76), respectively. No serious adverse events were reported during the trial. CONCLUSION: Unboosted fosamprenavir should not be used concomitantly with posaconazole.
Upload full text